Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (301-310 of 426) with videos related to

Pageof 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate CancerYingming Li, Rendong Yang, Christine M Henzler, et al.
European Urology|July 27, 2019
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Beshara Sheehan, Ruth Riisnaes, et al.
British Journal of Cancer|January 28, 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerA H M Reid, G Attard, L Ambroisine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 resultsMichael J Morris, Arturo Molina, Eric J Small, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
The Journal of Clinical Investigation|September 26, 2023
The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancerBeth Adamson, Nicholas Brittain, Laura Walker, et al.
Science Translational Medicine|November 6, 2015
Plasma AR and abiraterone-resistant prostate cancerAlessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancerS Halabi, S Dutta, C M Tangen, et al.
Investigational New Drugs|October 23, 2019
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Pageof 43

Showing results (301-310 of 426) with videos related to

Sort By:
Pageof 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate CancerYingming Li, Rendong Yang, Christine M Henzler, et al.
European Urology|July 27, 2019
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Beshara Sheehan, Ruth Riisnaes, et al.
British Journal of Cancer|January 28, 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerA H M Reid, G Attard, L Ambroisine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 resultsMichael J Morris, Arturo Molina, Eric J Small, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
The Journal of Clinical Investigation|September 26, 2023
The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancerBeth Adamson, Nicholas Brittain, Laura Walker, et al.
Science Translational Medicine|November 6, 2015
Plasma AR and abiraterone-resistant prostate cancerAlessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancerS Halabi, S Dutta, C M Tangen, et al.
Investigational New Drugs|October 23, 2019
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Pageof 43